MANILA, PHILIPPINES — Pharmally’s financial statement for 2020 shows that its sales that year was a whopping P7.49 billion – indicating that all these may have come solely from the P7.9 billion contracts that it got from the government.
After the Duterte government awarded Pharmally Pharmaceutical Corporation P7.9 billion worth of contracts in 2020 despite the latter having only P625,000 in paid-up capital, the newly registered company declared a net income of P264.7 million that year.
The company – whose executives have links to an ex-adviser of President Rodrigo Duterte and some of them wanted in Taiwan – is poised to earn more as the government has awarded them at least four additional contracts in 2021 totalling P2.3 billion.
These are:
- P507.3 million for 517,613 PPE (personal protective equipment sets) for P980 per unit; awarded by Procurement Service-Department of Budget and Management (PS-DBM) on May 19, 2021
- P774.3 million for 17,000 RT-PCR test kits for P45,550 per unit; awarded by PS-DBM on June 2, 2021
- P37.9 million for 2 million face shields for P18.88 per unit; awarded by the Department of Health (DOH) on June 11, 2021
- P1 billion for 26,970 RT-PCR test kits for P37,450 per unit; awarded by PS-DBM on July 26, 2021
Pharmally’s financial statement for 2020 shows that its sales that year was a whopping P7.49 billion – indicating that all these may have come solely from the P7.9 billion contracts that it got from the government.
Duterte, Malacañang, and COVID-19 plan chief implementer Carlito Galvez Jr. have all defended the government deals with Pharmally, saying it was the supplier who could deliver at the time.
This was despite former PS-DBM chief Lloyd Christopher Lao acknowledgment before senators that he could have been negligent in vetting suppliers like Pharmally. and Senator Risa Hontiveros’ revelation that Pharmally’s biggest shareholder, Huang Tzu Yen, and his father had been wanted for various forms of financial fraud in Taiwan since December 2020.
Rappler’s investigation shows how these companies is connected through a network to Yang.
From the Securities and Exchange CommissionHuge costs and expenses
Although it won P7.9 billion in pandemic contracts in 2020, and recorded a P7.09 billion cost of sales, Pharmally Pharma reported a P7.07 billion cost of inventory.
Its gross profit was further slashed when it incurred P42 million in general and administrative expenses. What ate up the company’s general and administrative expenses was P33.1 million in donations, but its financial statement provided no further detail on what kind of donations these were, and who they were given to.
All these left Pharmally Pharma P264 million in net income, driving its total assets to P284 million – a giant leap from its a little over half a million in assets in 2019.
Venture with another new firm
Of at least four pandemic contracts that Pharmally bagged in 2021, documents for which were accessed by Rappler from public databases, one was awarded by the DOH to Pharmally’s joint venture with another young company, Business Beyond Limits OPC (BBLOPC).
This was for 2 million pieces of face shields for P18.88 each, or a total of P37.9 million, awarded on June 11, 2021.
DOH bid documents show that nine suppliers joined the pre-bid conference on March 1, 2021. Pharmally Pharma did not attend.
On March 15, 2021, when the DOH opened the bids, Pharmally Pharma in joint venture with BBLOPC joined. They had the second lowest bid, with Nikka Trading as the lowest bid.
However, Nikka Trading was declared non-responsive, and the DOH decided to go with Pharmally and BBLOPC.
According to Securities and Exchange Commission (SEC) documents, BBLOPC was incorporated in February 2019 to import, distribute, and trade medical supplies.
It had a single director, Sophia Mercedes Custodio, who subscribed P10 million worth of share capital. This amount remained the same up to yearend 2020.
BBLOPC’s nominee in its article of incoporation in 2019, Krizle Grace Mago, is the authorized representative of Pharmally Pharma in two of its 2021 contracts.
